Patent · US Active

Biomarkers for risk prediction of mortality

US10557858B2 · kind B2 · utility

6Cited by

0References

23Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Roberto Latini · Milano, IT
Serge Masson · Monza, IT
Dirk Block · Bichl, DE
Christian Zaugg · Rheinfelden, CH
Thomas Dieterle · Freiburg (Elbe), DE
Edelgard Kaiser · Chur, CH
Johann Karl · Peißenberg, DE
Vinzent Rolny · Munich, DE
Ursula-Henrike Wienhues-Thelen · Krailling, DE

Key dates

Filing date	Apr 28, 2017
Grant date	Feb 11, 2020
Priority date	—
Expiry date	Apr 28, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/325
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.